Pancreatic cancer combo trial halted after just one patient
NCT ID NCT06069778
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to see if adding the experimental drug BNT321 to standard chemotherapy (mFOLFIRINOX) after surgery could help prevent pancreatic cancer from coming back. It was designed for people whose tumors were fully removed. However, the trial was stopped early after enrolling only one person, so no conclusions can be drawn about safety or effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical University of South Carolina (MUSC)
Charleston, South Carolina, 29425, United States
-
Valkyrie Clinical Trials
Los Angeles, California, 90067, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new drug combo shrink Hard-to-Treat tumors?